On January 7, 2022 Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, reported that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held January 10–13, 2022 (Press release, Palatin Technologies, JAN 7, 2022, https://www.prnewswire.com/news-releases/palatin-to-present-at-hc-wainwright-bioconnect-conference-301456337.html [SID1234598429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Carl Spana, PhD, President and Chief Executive Officer will provide an update on the Company’s pipeline, including the ongoing pivotal Phase 3 MELODY-1 study of PL9643 in patients suffering from dry eye disease.

The Company’s presentation will be available for on demand listening beginning at 7:00 a.m. ET on Monday, January 10, 2022, through the H.C. Wainwright BioConnect conference portal.

To request a one-on-one meeting with Palatin during the conference, please contact your H.C. Wainwright representative or email [email protected].